Fulcrum Therapeutics

Fulcrum Therapeutics, Sickle cell disease, Clinical hold, FDX-6058

Fulcrum’s Sickle Cell Disease Program Resumes as FDA Lifts 6-Month Hold

Anika Sharma

Fulcrum Therapeutics’ ambitions in the realm of sickle cell disease (SCD) have been revitalised after a six-month hiatus. The FDA ...